The Hong Kong stock exchange has stressed the importance of having sophisticated investors for pre-revenue biotech companies seeking an initial public offering (IPO) in the city, as it is fielding a strong pipeline of hopefuls looking to capitalise on investors’ enthusiasm in health-related stocks.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
